Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus — Stella

Recruiting

Back to Progressive Keratoconus trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Glaukos Investigative Site, Dothan, Alabama

Glaukos Investigative Site, Teaneck, New Jersey

Glaukos Investigative Site, Westerville, Ohio

Key details

Phase

Early testing / Safety & dosing

Sponsor

Glaukos Corporation

Enrollment target

~150 participants

Started

March 2022

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 55 Years

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov